Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) reached a new 52-week low on Wednesday . The company traded as low as $2.57 and last traded at $2.61, with a volume of 132,511 shares changing hands. The stock had previously closed at $2.61.

Separately, Maxim Group reduced their price target on Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 21st.

The firm’s market cap is $39.42 million. The stock’s 50-day moving average price is $2.92 and its 200 day moving average price is $5.42.

In other news, SVP David J. Marguglio sold 4,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $8.08, for a total transaction of $32,320.00. Following the completion of the transaction, the senior vice president now owns 102,227 shares in the company, valued at $825,994.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.